Colon Cancer OS Rates High with Neoadjuvant Immunotherapy
Summary
In patients with locally advanced mismatch repair-deficient colon cancer taking neoadjuvant nivolumab plus ipilimumab, no recurrences or deaths occurred after nearly five years. Medscape Medical News
Description from Medscape.
Who is covering this
-
Colon Cancer OS Rates High with Neoadjuvant Immunotherapy
In patients with locally advanced mismatch repair-deficient colon cancer taking neoadjuvant nivolumab plus ipilimumab, no recurrences or deaths occurred after nearly five years. Medscape Medical News
Comments
Comments need JavaScript.